Craig Hofmeister

Title: Craig Hofmeister: Innovator in Chimeric Antigen Receptor Technology

Introduction

Craig Hofmeister is a prominent inventor based in Columbus, OH (US). He has made significant contributions to the field of immunotherapy, particularly in the development of chimeric antigen receptors (CAR) for cancer treatment. With a total of 4 patents, Hofmeister's work is paving the way for innovative approaches to combat multiple myeloma.

Latest Patents

Hofmeister's latest patents focus on CS1-specific chimeric antigen receptor engineered immune effector cells. These patents disclose CARs that can specifically recognize tumor-associated antigens (TAA) on multiple myeloma (MM) cells. The patents also detail immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Furthermore, the methods for providing anti-tumor immunity in subjects with MM through the adoptive transfer of these engineered immune effector cells are also outlined.

Career Highlights

Craig Hofmeister is associated with the Ohio State Innovation Foundation, where he continues to advance research in immunotherapy. His innovative work has garnered attention in the scientific community, contributing to the understanding and treatment of cancer.

Collaborations

Hofmeister collaborates with notable colleagues, including Jianhua Yu and Jianhong Chu. Their combined expertise enhances the research and development of cutting-edge therapies in the field.

Conclusion

Craig Hofmeister's contributions to the field of immunotherapy through his innovative patents and collaborations are making a significant impact in the fight against cancer. His work exemplifies the potential of engineered immune effector cells in providing effective treatments for multiple myeloma.